Emerging Microbiology Tests and Companies Developing New Technologies and Products
Venture Planning Group
February 10, 2012 650 Pages - SKU: VPG6801241
|
|
This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products.
Contains 650 pages and 47 tables
Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.
|
- 1. AIDS
- a. Background
- 0 Structure and Composition
- 0 Classification
- 0 Origin of AIDS
- 0 Animal Lentivirus Systems
- 0 Virus Receptos
- 0 HIV Infections in Humans
- - Pathogenesis & Pathology: Overview of HIV Infection Course
- 0 CD4T Lymphocytes and Memory Cells
- 0 Monocytes and Macrophages
- 0 Lymphoid Organs
- 0 Neural Cells
- 0 Viral Coinfections
- - Clinical Findings
- 0 Plasma Viral Load
- 0 Pediatric AIDS
- - Neurologic Disease
- - Opportunistic Infections
- - Cancer
- 0 Immunity
- - Virus Isolation
- - Serology
- - Detection of Viral Nucleic Acid and Antigens
- 0 Infectivity
- 0 Epidemiology
- - Worldwide Spread of AIDS
- - United States
- - Routes of Transmission
- b. Diagnostic Tests
- 0 Laboratory Diagnosis
- - Enzyme Immunoassay Interpretation
- - Specific, Sensitivity, and Predictive Value of Enzyme Immunoassays
- 0 Competition Assays
- 0 Western Blot Technique
- 0 Immuno-Fluorescence Assay (IFA)
- 0 Radioimmunoprecipitation
- 0 HIV-1/HIV-2 Combination Testing
- 0 Methods of HIV-Antigen Detection
- 0 Antigen Assays and Blood Screening
- 0 Urine Tests
- 0 Immunopathogenic Mechanism of HIV Infection
- 0 DNA Probes
- - Overview
- - Quantitative Polymerase Chain Reaction
- - In Situ PCR
- - Needed Improvements
- 0 Viral Load/Drug Resistance Testing
- 0 Genotype and Phenotype Testing
- 0 Blood Banking Consideration
- c. Vaccines and Drugs
- - Antiviral Drugs
- - Vaccines Against HIV
- 0 Transmission of HIV in Blood Products
- 0 HIV Transmission in Transplant and Artificial Insemination Recipients
- 2. Adenovirus
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- d. Adeno-Associated Viruses(AAV)
- 3. Aeromonas
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 4. Anthrax/Bacillus Anthracis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 5. Arboviruses
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 6. Babesiosis
- a. Background
- 7. Bacillary Epithelioid Angiomatosis (BEA) And Other Bartonella (Rochalimaea)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 8. Blastocystis Hominis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 9. Brucella
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 10. Campylobacter
- a. Background
- b. Diagnostic Tests
- 0 Identification from Culture
- c. Vaccines and Drugs
- 11. Candida
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 12. Chagas Disease
- a. Background
- 13. Chancroid
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 14. Chlamydia
- a. Background
- 0 Chlamydia Psittaci
- 0 Chlamydia Pneumoniae
- 0 Chlamydia Trachomatis
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 15. Clostridium Difficile
- a. Background
- 0 Pediatric Infections
- 0 Epidemiology
- b. Diagnostic Tests
- 0 Counterimmunoelectrophoresis
- 0 Fluorescent-Antibody Assays
- 0 Poloymerase Chain Reactions
- c. Drugs and Vaccines
- 16. Coronaviruses
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 17. Coxsackieviruses
- a. Background
- 0 Herpangina
- 0 Hand-foot-and-mouth syndrome
- 0 Hepidemic Conjuctivitis
- 0 Pharingitis
- 0 Epidemic Pleurodynia
- 0 Myodarditis,Pericarditis
- 0 Overwhelming Infection of the Newborn
- 0 Acute Aseptic Meningitis
- 0 Undifferentiated Febrile Illness
- 0 Fever with upper respiratory infection
- 0 Encephalitis
- 0 Asymptomatic Infection
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 18. Creutzfeldt-Jakob’s Disease
- a. Background
- 0 Blood Transmission
- b. Diagnostic Tests
- 0 Major Commercial and Academic Players
- - Bayer
- - Disease Sciences/Bio Tec Global
- - Imperial College of Medicine
- - Ortho-Clinical Diagnostics
- - Pall
- - ProMetic Life Sciences
- - Proteome Sciences/Idexx
- - Q-One Biotech
- - Serono
- - U.S. Agricultural Research Service
- c. Vaccines
- 19. Cryptosporidium Parvum
- a. Background
- b. Diagnostic Tests
- 0 Histologic
- 0 Laboratory Parasitology
- 0 Serodiagnosis
- c. Vaccines and Drugs
- 20. Cyclospora Cayetanensis
- a. Background
- 0 Asymptomatic Infection
- 0 Diarrhea in Immunocompetent Persons
- 0 Diarrhea in Immunocompromisedersons
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 21. Cytomegalovirus
- a. Background
- 0 Chorioretinitis
- 0 Gastrointestinal
- 0 Central Nervous System Disease
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 22. Ebola Virus
- a. Background
- 0 Epidemiology
- 0 Hemorrhagic Fever
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 23. E. Coli
- a. Background
- 0 Role of Escherichia Coli in
- Causing Diarrhea
- 0 EPEC
- 0 ETEC
- 0 EIEC
- 0 EHEC
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 24. EchoVirus
- a. Background
- 0 Acute Aseptic Miningitisis
- 0 Encephalitis
- 0 Exanthems
- 0 Respiratory Disease
- 0 Myope;ricarditis
- 0 Neonatal Infections
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 25. Encephalitis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 26. Enteroviruses
- a. Background
- b. Diagnostic Tests
- 0 Viral Isolation and Identification
- 0 Antibody Tests
- c. Vaccines and Drugs
- 27. Epstein-Barr Virus
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 28. Giardia Lamblia
- a. Background
- 0 Life Cycle and Morphology
- 0 Morphology of Trophozoites
- 0 Clinical Disease
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 29. Gonorrhea
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 30. Granuloma Inguinale
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 31. Hantavirus
- a. Background
- 0 Identification of the Agent
- 0 Transmission
- 0 Other Rodent Hantaviruses
- 0 Distribution
- 0 Hantavirus Diseases
- 0 Epidemiology
- 0 Addendum in Proof-Northeastern Connection
- 0 Previously Unknown Pathogens
- 0 Cases Nationwide
- b. Diagnostic Tests
- 0 An Immunohistochemistry Approach
- 0 Hantavirus Rapid Diagnostic Test
- 0 ELISA Diagnosis of Hantavirus Pulmonary Syndrome
- 0 IgG ELISA
- 0 IgM Capture ELISA
- c. Vaccines and Drugs
- 32. Helicobacter Pylori
- a. Background
- 0 Pathogenesis
- 0 Role in Peptic Ulcer Disease
- 0 Role in Gastric Cancer
- 0 Nonulcer Dyspepsia
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Specific Therapeutic Regimens
- 0 Who Should Be Treated?
- 0 Participants in Controlled Clinical Trials
- 0 Patients with Refractory Peptic Ulcer
- 0 Patients with Refractory NUD
- 0 Patients in High-Risk Groups for Gastric Cancer
- 33. Hepatitis
- a. Background
- b. Hepatitis A
- c. Hepatitis B
- d. Hepatitis C
- 0 Classification
- 0 Transmission of Infection
- 0 Occupational Hazards
- 0 Acute Hepatitis
- 0 Diagnosis of Acute Infection
- 0 Chronic Hepatitis
- 0 HCV and Other Chronic Liver Diseases
- 0 Alcoholic Liver Disease
- 0 Hepatitis B Coinfection
- 0 Cirrhosis and Hepatocellular Carcinoma
- 0 Diagnostic Tests
- 0 Possible Indications for HCV RNA Testing
- 0 Conclusions and Future Direction
- e. Hepatitis D
- 0 Historical Perspective
- 0 Epidemiology
- 0 HBV-HDV "Coinfection" vs. "Superinfection"
- 0 Methods of Detecting HDV
- 0 Prevention
- f. Hepatitis E
- 0 Background
- 0 Prevalence of the Disease
- 0 Diagnostic Tests
- 0 Epidemiologic Serosurveys
- 0 Serologic Cross-Reactivity
- g. Hepatitis G
- 0 Vaccines and Drugs
- 34. Herpes Simplex Virus
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 35. Human Herpes Virus-6 (HHV-6)
- a. Background
- 0 HIV-6 Infections
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 36. Influenza Viruses
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 37. Legionella
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 38. Lyme Disease
- a. Background
- 0 Clinical Description
- 0 Clinical Case Definition
- 0 Laboratory Criteria for Diagnosis
- 0 Case Classification
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 39. Lymphogranuloma Venereum (LGV)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 40. Malaria
- a. Background
- b. Diagnostic Tests
- 0 Potential Diagnositic Problems with Positive Patients from Non-endemic Areas
- - Patient
- - Laboratory
- - Physician
- c. Vaccines and Drugs
- 41. Measles (Rubeola)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 42. Meningitis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Development of Polysaccharide Vaccines
- 0 Quadrivalent Vaccine Development
- 0 Meningococcal A.C.Y. & W-135 Vaccines
- 0 Efficacy of Group C Vaccine
- 0 Efficacy of Group A Vaccine
- 0 Combinations of Group A and C Vaccines
- 0 Group B Efficacy Trials
- 0 Future Direction
- 43. Microsporidium
- a. Background
- 0 Prevalence and Geographic Distribution
- 0 Sources of Human Infection and Transmission
- b. Diagnostic Tests
- 0 Light Microscopic Examination of Stool Specimens By Chromotrope Staining
- 0 Stool Concentration Methods
- 0 Chemofluorescent Agents
- 0 Giemsa Staining of Stool Specimens
- 0 Cytologic Diagnosis
- 0 Histologic Examination
- 0 Electron Microscopy
- 0 Examination of Bodily Fluids
- 0 Examination of Tissue Sections
- 0 Immunofluorescence Detection Procedures
- 0 Serology
- 0 Cell Culture
- 0 Approach to Diagnosis
- 0 Evaluation of Patients with Presumptive Intestinal Microsporidiosis
- 0 Evaluation of Patients with Presumptive Ocular Microsporidiosis
- c. Vaccines and Drugs
- 44. Mononucleosis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 45. Mumps
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Efficacy of Vaccination
- 0 Future Issues
- 46. Mycoplasma
- a. Background
- 0 Ureaplasma Urealyticum & Mycoplasma Hominis
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 47. Papillomaviruses
- a. Background
- 0 HPV in Cancer
- 0 Cervical Neoplasm
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Prevention
- 48. Parvovirus B19
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 49. Pneumonia
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 50. Polyomaviruses
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 51. Pseudomonas Aeruginosa
- a. Background
- 0 Virulence Factors
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 52. Rabies
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 53. Respiratory Syncytial Virus (RSV)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 54. RhinoViruses
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 55. RotaVirus (REOVIRUS)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 56. Rubella(MEASLES)
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Developing Countries
- 0 Elimination and Eradication of Measles
- 0 New Developments
- 57. Salmonellosis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 58. Septicemia
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 59. Shigellosis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 60. Staphylococcus Aureus
- a. Background
- 0 The Genus Taphylococcus
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Prevention
- 61. Streptococci
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 0 Group A Streptococci
- 0 Group B Streptococci
- 62. Syphilis
- a. Background
- b. Diagnostic Tests
- 0 Biopsy
- 0 Rabbit Infectivity Testing
- 0 Other Diagnostic Modalities
- c. Vaccines and Drugs
- 0 Syphilis and HIV Infection
- 0 Syphilis As a Cofactor for HIV Transmission
- 0 Basic Science Issues
- 63. Toxoplasmosis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 64. Trichomonas Vaginalis
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 65. Tuberculosis
- a. Background
- b. Diagnostic Tests
- 0 Microscopic Characteristics
- 0 Cultural Characteristics
- 0 Detection of Antibodies
- 0 Skin Tests
- 0 MDRTB
- c. Vaccines and Drugs
- 66. Vibrio
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 67. West Nile Virus
- a. Background
- - Clinical Syndromes
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 68. Yersina
- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- List of Tables
- Major Companies Developing or Marketing AIDS Tests
- Major Companies Developing or Marketing AdenovirusTests
- Major Companies Developing or Marketing BartonellaTests
- Major Companies Developing or MarketingCampylobacter Tests
- Major Companies Developing or Marketing CandidaTests
- Major Companies Developing or Marketing ChlamydiaTests
- Major Companies Developing or Marketing ClostridiumTests
- Major Companies Developing or Marketing CoronavirusTests
- Major Companies Developing or Marketing CryptosporidiumTests
- Major Companies Developing or Marketing CMV Tests
- Major Companies Developing or Marketing EchovirusTests
- Major Companies Developing or Marketing EnterovirusTests
- Major Companies Developing or Marketing EBV Tests
- Major Companies Developing or Marketing GiardiaTests
- Major Companies Developing or Marketing GonorrheaTests
- Major Companies Developing or Marketing HantavirusTests
- Major Companies Developing or Marketing HelicobacterPylori Tests
- Major Companies Developing or Marketing HepatitisTests
- Major Companies Developing or Marketing HerpesTests
- Major Companies Developing or Marketing InfluenzaTests
- Major Companies Developing or Marketing LegionellaTests
- Major Companies Developing or Marketing Lyme DiseaseTests
- Major Companies Developing or Marketing LymphogranulomaTests
- Major Companies Developing or Marketing MalariaTests
- Major Companies Developing or Marketing MeaslesTests
- Major Companies Developing or Marketing MeningitisTests
- Major Companies Developing or Marketing MicrosporidiumTests
- Major Companies Developing or MarketingMononucleosis Tests
- Major Companies Developing or Marketing Mumps Tests
- Major Companies Developing or Marketing MycoplasmaTests
- Major Companies Developing or Marketing PapillomaVirus Tests
- Major Companies Developing or Marketing ParvovirusTests
- Major Companies Developing or Marketing PneumoniaTests
- Major Companies Developing or Marketing RSV Tests
- Major Companies Developing or Marketing RotavirusTests
- Major Companies Developing or Marketing RubellaTests
- Major Companies Developing or Marketing SalmonellaTests
- Major Companies Developing or Marketing SepticemiaTests
- Major Companies Developing or Marketing ShigellaTests
- Major Companies Developing or Marketing StaphylococciTests
- Major Companies Developing or MarketingStreptococci Tests
- Major Companies Developing or Marketing SyphilisTests
- Major Companies Developing or Marketing ToxoplasmosisTests
- Major Companies Developing or Marketing TrichomonasTests
- Major Companies Developing or Marketing TuberculosisTests
- Major Companies Developing or Marketing West NileTests
- Major Companies Developing or Marketing Yersinia Tests
Share this report
Other tasks Related Markets Microbiology & Virology Reports- In Vitro Diagnostics - A Global Market Overview
- In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers & Microbiology Culture) – Global Trends & Forecasts to 2016
- 2012 European Microbiology Testing Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
- 2012 Global Transfusion Diagnostic Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts for Typing, Grouping and Infectious Disease Screening Tests by Country
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
